Abstract 4891
Background
Stereotactic body radiation therapy (SBRT) has been shown to have high efficacy to early-stage hepatocellular carcinoma (HCC) and is expected as an alternative to radiofrequency ablation (RFA). However, how liver function is impaired by SBRT, an important factor in the therapy for HCC, is uncertain. In this study, we compared the impact of SBRT on liver function and that of RFA.
Methods
We retrospectively analyzed 140 patients with single small (≤3 cm) hepatocellular carcinoma treated with SBRT or RFA between January 2014 and January 2019 in Kurashiki Central Hospital. A median age was 75 years, and 101 patients were male. Liver function was assessed by the albumin-bilirubin (ALBI) score before treatment (pre-ALBI) and 3 months after treatment (post-ALBI). Patients in the SBRT group were matched at a 1:1 ratio with patients treated with RFA by using propensity score method, and post-ALBI scores were compared between the two groups.
Results
Among the 140 patients, 42 and 98 patients were treated with SBRT and RFA, respectively. Before matching, patients in SBRT group were significantly older than patients in RFA group (78 vs. 72.5 years, p =.038), while patients’ sex, etiology of liver diseases, tumor size, tumor location and baseline liver function (both ALBI score and Child-Turcotte-Pugh score) were similar between the two groups. In SBRT group, median pre-ALBI and post-ALBI scores were -2.40 and -2.30, respectively, and the difference was not significant (p =.336). After propensity score matching, all the baseline characteristics were well balanced, and post-ALBI scores were not significant different between SBRT and RFA groups (-2.27 vs. -2.30, p =.828).
Conclusions
In our study, the impact of SBRT on liver function was comparable to that of RFA. Our findings help to promote SBRT as an expecting alternative treatment for early-stage HCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5458 - Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120 mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen.
Presenter: Philippe Ruszniewski
Session: Poster Display session 2
Resources:
Abstract
1234 - Analysis of PD-1/PD-L1 blockade biomarker and immune infiltrates in Gastroenteropancreatic neuroendocrine carcinoma
Presenter: Jia Zhang Xing
Session: Poster Display session 2
Resources:
Abstract
1517 - Diabetes Is Associated With Pancreatic Neuroendocrine Tumors Growth and Metastasis
Presenter: Zhiyao Fan
Session: Poster Display session 2
Resources:
Abstract
2145 - Investigation of the reclassification of G1/G2 pancreatic neuroendocrine neoplasms by WHO 2017 classification
Presenter: Takahiro Yokose
Session: Poster Display session 2
Resources:
Abstract
3134 - Treatment with somatostatin analogues after radiopeptide therapy
Presenter: Daria Handkiewicz Junak
Session: Poster Display session 2
Resources:
Abstract
2191 - Safety and Tolerability of Surufatinib in Western Patients with Solid Tumors
Presenter: Erika Hamilton
Session: Poster Display session 2
Resources:
Abstract
3253 - The impact of tumour absorbed dosimetry with survival outcomes after peptide receptor radionuclide therapy in metastatic neuroendocrine tumours.
Presenter: Rahul Ladwa
Session: Poster Display session 2
Resources:
Abstract
3581 - Opportunist and Serious Infections in Patients with Neuroendocrine Tumors Treated With Everolimus: A Multicenter Study of Real World Patients
Presenter: Carine Mauro
Session: Poster Display session 2
Resources:
Abstract
5374 - Establishment of Prognostic Nomogram Based on the Metastatic Lymph Nodes Ratio for Patients with Gastric Neuroendocrine Tumour
Presenter: yaobin lin
Session: Poster Display session 2
Resources:
Abstract
3951 - Neutrophil-lymphocyte ratio as an independent predictive factor in Neuroendocrine Neoplasms
Presenter: Sofia Ferreira
Session: Poster Display session 2
Resources:
Abstract